drugset / Trial / NCT00376701
Combination Therapy for Age-Related Macular Degeneration.
Phase 2
Completed
103 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Canadian Retinal Trials Group · collabQLT Inc. · collab
RandomizedFactorialOpen-labelTreatment
Summary
The primary purpose of the study is to investigate whether patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration, receiving triple or double therapy compared to monotherapy with Avastin will reduce the intervention rate with equivalent safety and efficacy.
Timeline
- Start
- 2006-09
- Primary completion
- 2009-04
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |